# Fulcrum Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/fulcrum-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.fulcrumtx.com
- Total disclosed funding: $135M
- Latest round: Series B (Aug 24, 2018)
- Investors on record: 10

## About

Fulcrum Therapeutics, Inc. is a US-based biopharmaceutical company focused on developing innovative therapies for genetically defined diseases, particularly those with significant unmet medical needs. Founded in 2016 and led by Alex C. Sapir, Fulcrum Therapeutics, Inc. operates out of Cambridge, US, and specializes in targeted treatments for genetic disorders. In August 2026, Fulcrum Therapeutics, Inc., a portfolio company of Boxer Capital, Samsara BioCapital, Perceptive Advisors, EcoR1 Capital, Casdin Capital, Alyeska Investment Group, Monashees, Timefolio Capital, Section 32, 6 Dimensions Capital, Casdin Capital, Foresite Capital, Fidelity Investments, Sanofi Ventures, Leerink Partners, GV, and Third Rock Ventures, agreed to merge into Slate Medicines, a portfolio company of Forbion, Foresite Capital, and RA Capital Management. The transaction is subject to customary closing condition and is expected to be completed in the fourth quarter of 2026. Following the transaction, the combined company is expected to be renamed Slate Medicines and trade on Nasdaq under the ticker symbol SLTE. The current CEO is Alex Sapir, who has a history of leading biotech initiatives.Fulcrum Therapeutics is dedicated to developing innovative treatments for patients with genetically defined diseases, particularly those with high unmet medical needs. The company's lead product, pociredir, is currently undergoing clinical trials aimed at treating sickle cell disease (SCD), focusing on modulating gene expression to address the underlying genetic causes of this condition. In addition to pociredir, Fulcrum is actively exploring other programs within its research pipeline, including potential treatments for beta-thalassemia. The target customer base includes healthcare providers and institutions that cater to affected patient populations, primarily in North America and Europe, where the prevalence of these genetic disorders is significant. By concentrating on the scientific advancements necessary for effective therapies, Fulcrum aims to enhance patient outcomes and quality of life in these regions.Fulcrum Therapeutics engages in a structured transaction model that typically involves partnerships and collaborations with healthcare organizations and research institutions. The company reported a revenue of USD 80.00 mn for the year 2024, with an EBITDA of USD 20.30 mn. Revenue is generated primarily through clinical trial funding and potential future product sales once therapies receive regulatory approval. The company's flagship product, pociredir, represents a significant focus in its revenue strategy, aligning with the needs of healthcare providers seeking innovative treatment options for SCD patients. While specific pricing plans for products are not disclosed, the company is positioned to establish pricing based on the value provided by its therapeutics and their ability to address unmet medical needs in the genetic disease market. The firm’s revenue model may also be complemented by potential licensing agreements and collaborations with biotechnology firms that share similar therapeutic goals.

## Funding rounds

- Series B, Aug 24, 2018, $80M — Fidelity Investments, Leerink Partners, Sanofi Ventures, Foresite Capital, Casdin Capital, 6 Dimensions Capital, Section 32, Timefolio Capital
- Series A, May 10, 2017 — GV
- Series A, Jul 19, 2016, $55M — Third Rock Ventures

## Investors

- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A
- GV (https://capitalatlas.ai/funds/gv) — Series A
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B
- Leerink Partners — Series B
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series B
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B
- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series B
- Section 32 (https://capitalatlas.ai/funds/section-32) — Series B
- Timefolio Capital — Series B